0.384
price up icon3.36%   0.0125
pre-market  Pre-mercato:  .38   -0.004   -1.04%
loading
Precedente Chiudi:
$0.3715
Aprire:
$0.3611
Volume 24 ore:
12.98M
Relative Volume:
0.52
Capitalizzazione di mercato:
$19.58M
Reddito:
-
Utile/perdita netta:
$-12.89M
Rapporto P/E:
-0.1518
EPS:
-2.53
Flusso di cassa netto:
$-11.95M
1 W Prestazione:
+14.18%
1M Prestazione:
+97.94%
6M Prestazione:
-69.03%
1 anno Prestazione:
-77.93%
Intervallo 1D:
Value
$0.3611
$0.41
Intervallo di 1 settimana:
Value
$0.3165
$0.41
Portata 52W:
Value
$0.1634
$2.3099

Plus Therapeutics Inc Stock (PSTV) Company Profile

Name
Nome
Plus Therapeutics Inc
Name
Telefono
737.255.7194
Name
Indirizzo
4200 MARATHON BLVD., AUSTIN, TX
Name
Dipendente
21
Name
Cinguettio
@plustxinc
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
PSTV's Discussions on Twitter

Confronta PSTV con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
PSTV
Plus Therapeutics Inc
0.384 17.15M 0 -12.89M -11.95M -2.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-17 Iniziato D. Boral Capital Buy
2021-01-25 Iniziato Ladenburg Thalmann Buy
2020-10-16 Iniziato Maxim Group Buy

Plus Therapeutics Inc Borsa (PSTV) Ultime notizie

pulisher
Jul 20, 2025

Is Plus Therapeutics Inc. a good long term investmentRapid growth opportunities - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

What drives Plus Therapeutics Inc. stock priceOutstanding yields - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

What analysts say about Plus Therapeutics Inc. stockFree Investment Portfolio Suggestions - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

Plus Therapeutics Inc. Stock Analysis and ForecastOutstanding growth strategies - Autocar Professional

Jul 19, 2025
pulisher
Jul 17, 2025

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Yahoo

Jul 17, 2025
pulisher
Jul 16, 2025

Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN

Jul 16, 2025
pulisher
Jul 15, 2025

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases | PSTV Stock News - GuruFocus

Jul 15, 2025
pulisher
Jul 15, 2025

Plus Therapeutics Announces Clinical Trial Presentation and Educational Symposium at 2025 SNO/ASCO CNS Metastases Conference - Nasdaq

Jul 15, 2025
pulisher
Jul 15, 2025

Plus Therapeutics Presents ReSPECT-LM Clinical Trial - GlobeNewswire

Jul 15, 2025
pulisher
Jul 15, 2025

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases - TradingView

Jul 15, 2025
pulisher
Jul 11, 2025

Plus Therapeutics Advances Pediatric Brain Tumor Treatment with New Clinical Study - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference - GlobeNewswire

Jul 11, 2025
pulisher
Jul 10, 2025

Plus Therapeutics Announces Two CNSide Presentations at the Upco - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference | PSTV Stock News - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Plus Therapeutics' CNSide Showcases Innovative CSF Assay Data at SNO/ASCO CNS Metastases Conference 2025 - Nasdaq

Jul 10, 2025
pulisher
Jul 10, 2025

Revolutionary CNS Cancer Detection: Plus Therapeutics Unveils Game-Changing Clinical Data at Major Conference - Stock Titan

Jul 10, 2025
pulisher
Jul 09, 2025

Plus Therapeutics Soars 10.51% on Promising Clinical Trial Results - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Plus Therapeutics begins treatment in REYOBIQ dose optimization trial By Investing.com - Investing.com South Africa

Jul 09, 2025
pulisher
Jul 08, 2025

Plus Therapeutics Announces Initial Patients Successfully - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Plus Therapeutics begins treatment in REYOBIQ dose optimization trial - Investing.com

Jul 08, 2025
pulisher
Jul 08, 2025

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases | PSTV Stock News - GuruFocus

Jul 08, 2025
pulisher
Jul 08, 2025

Plus Therapeutics announces initial patients successfully treated in ReSPECT-LM dose optimization trial for Reyobiq™ in leptomeningeal metastases - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Plus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases Treatment - Nasdaq

Jul 08, 2025
pulisher
Jul 08, 2025

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases - The Manila Times

Jul 08, 2025
pulisher
Jul 08, 2025

Breakthrough Brain Cancer Drug REYOBIQ Achieves 80% Tumor Reduction in Phase 1 Trial, Advances to Next Stage - Stock Titan

Jul 08, 2025
pulisher
Jul 07, 2025

Plus Therapeutics shares fall 3.72% premarket after FDA clearance of Reyobiq for childhood brain cancer. - AInvest

Jul 07, 2025
pulisher
Jul 03, 2025

Plus Therapeutics, Inc. shares fall 1.63% premarket after Novartis' Cosentyx fails in Phase III GCAptAIN study. - AInvest

Jul 03, 2025
pulisher
Jul 01, 2025

Stock under $1with a very strong catalyst to buy and hold for a minimum of three years - AInvest

Jul 01, 2025
pulisher
Jun 30, 2025

Plus Therapeutics Advances Brain Cancer Treatment: FDA Green Light and $17.6M Boost for Critical Trial - Stock Titan

Jun 30, 2025
pulisher
Jun 29, 2025

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM - GuruFocus

Jun 29, 2025
pulisher
Jun 29, 2025

PSTV SEC FilingsPlus Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 29, 2025
pulisher
Jun 27, 2025

H.C. Wainwright Adjusts Price Target for Plus Therapeutics (PSTV) | PSTV Stock News - GuruFocus

Jun 27, 2025
pulisher
Jun 26, 2025

Plus Therapeutics Soars 25.71% on FDA Trial Approval - AInvest

Jun 26, 2025
pulisher
Jun 25, 2025

Plus Therapeutics (PSTV) Shares Surge After FDA Trial Clearance - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

PSTV Stock Update: D. Boral Capital Maintains Hold Rating for Plus Therapeutics | PSTV Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 24, 2025

Plus Therapeutics (PSTV) Restructures $15M Equity Financing to Minimize Dilution | PSTV Stock News - GuruFocus

Jun 24, 2025
pulisher
Jun 20, 2025

Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering - MSN

Jun 20, 2025
pulisher
Jun 19, 2025

Plus (PSTV) Upgraded to Buy: Here's Why - Nasdaq

Jun 19, 2025
pulisher
Jun 18, 2025

Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

Plus Therapeutics (PSTV) Sees Stock Dip Amid New Share Sale Fili - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering (PSTV:NASDAQ) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 18, 2025

Plus Therapeutics (PSTV) Announces Sale of 17 Million Shares | P - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Plus Therapeutics (PSTV) Announces Sale of 17 Million Shares | PSTV Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Plus Therapeutics Modifies Security Holders’ Rights - TipRanks

Jun 17, 2025
pulisher
Jun 13, 2025

Plus Therapeutics Plunges 10.89% Amid Institutional Shifts - AInvest

Jun 13, 2025
pulisher
Jun 10, 2025

Leptomeningeal Metastases Pipeline 2025: MOA, ROA, - openPR.com

Jun 10, 2025
pulisher
Jun 09, 2025

Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials - AlphaStreet

Jun 09, 2025
pulisher
Jun 06, 2025

Plus Therapeutics Appeals Nasdaq Delisting Decision - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Plus Therapeutics (NASDAQ:PSTV) Given New $20.50 Price Target at Ascendiant Capital Markets - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds - mx.advfn.com

Jun 05, 2025
pulisher
Jun 05, 2025

Ascendiant Capital raises Plus Therapeutics stock price target By Investing.com - Investing.com South Africa

Jun 05, 2025

Plus Therapeutics Inc Azioni (PSTV) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
Capitalizzazione:     |  Volume (24 ore):